维昇药业-B(02561)今日盘中大涨5.28%，引起了市场的广泛关注。
消息面上，公司核心产品注射用隆培生长激素（商品名：维臻高®/SKYTROFA®）已获得国家药品监督管理局的上市批准，用于治疗3岁及以上儿童及青少年的生长激素缺乏症。该产品是唯一一款在与短效人生长激素的对照试验中显示出长高疗效优效性的长效生长激素，其获批标志着公司进入了新的商业化阶段。
此外，公司已建立专业的商业化团队，并计划于2026年全面启动该产品的商业化。尽管公司同期发布的年度业绩显示亏损有所扩大，但市场显然更聚焦于核心产品获批这一重大里程碑所带来的长期增长潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.